Gilead has dominated the HCV drug market for years with unshakeable "absolute supremacy" since its new direct-acting antiviral (DAA) Sovaldi entered the market in December 2013. Its star HCV products Solvadi and Harvoni have led the market value of Gilead Sciences to the peak of USD 160 billion, ranking among TOP10 global pharmaceutical enterprises, which is quite legendary.
Gilead announced on December 14, 2016 that it had submitted to FDA the new drug application (NDA) of the new HCV compound drug of SOF/VEL/VOX for patients infected with HCV who have failed prior treatment with DAA regimens. This product will further perfect its HCV products and shore up its position in hepatitis C field. This article intends to compare the several main companies in the hepatitis C field, analyze the internal business mode of hepatitis C drug market, and focus on the future direction of Gilead.
I. Gilead landing on the position strongly, with unshakeable "supremacy"
According to statistics, there are nearly 200 million HCV patients in the world. Hepatitis C is the most common cause of liver cirrhosis and liver cancer. In the previous article Another New Progress in Hepatitis C Treatment: "Absolute Dominant" Gilead and "Latecomer" AbbVie, it mentions that there are mainly 6 genotypes and more than 50 subtypes of HCV.
Hepatitis C treatment has achieved breakthrough progress in recent years, from the initial interferon injection treatment and interferons in combination with antivirals, to the third-generation new DAAs. The following figure shows the several main targets of DAAs.
Read More
(All Rights Reserved)